**Core tip:** Many carcinomas, including colorectal cancer, gastric and nasopharyngeal cancer, are associated with elevated numbers of T regulatory (Treg) cells. It is suggested that Treg cells promote tumor development and metastasis by inhibiting the proliferation of effector T lymphocytes. LAP^+^CD4^+^ T cells, a recently identified subset of CD4^+^ Treg cells, have 50-fold more potent immunosuppressive ability than traditional CD4^+^CD25^+^ T cells. Here, we present several lines of evidence correlating LAP^+^CD4^+^ T cells with colorectal cancer progression.

INTRODUCTION
============

Colorectal cancer (CRC) is the third most common carcinoma in men and second most common in women, with \> 1 million new cases and \> 500000 deaths every year worldwide\[[@B1],[@B2]\]. CRC progression is a complex process involving interactions between host cellular immunity factors and the tumor, which take place in the so-called tumor microenvironment\[[@B3],[@B4]\]. This environment includes numerous factors that promote tumor growth, such as energy and nutrients in blood vessels, growth factors from immune cells and stromal cells, and proinflammatory mediators secreted by tumor cells\[[@B5]\]. The environment also contains numerous factors that can limit tumor growth, such as tumor-infiltrating immune cells and tertiary lymphoid structures\[[@B6]\]. This complex mixture of factors largely determines patient prognosis and serves as an attractive therapeutic target\[[@B6],[@B7]\].

Several studies have suggested that during CRC progression, peripheral regulatory T (Treg) cells and myeloid suppressor cells increase in the tumor microenvironment, which is associated with worse prognosis\[[@B8]-[@B10]\]. Part of the reason appears to be that these cell populations counteract the host\'s antitumor immune response\[[@B11]\]. Downregulating Treg cells can render antitumor responses more effective, which may improve prognosis in patients with CRC and other malignant carcinomas\[[@B12]\].

LAP^+^CD4^+^ T cells are a newly identified subset of Treg cells that express latent-associated peptide (LAP), and function within the latent transforming growth factor (TGF)-β complex to block interaction between TGF-β and receptors on immune cells\[[@B13]\]. Among the various Treg cell populations, LAP^+^CD4^+^ T cells are endowed with more potent immunosuppressive function than traditional CD4^+^CD25^+^Foxp3^+^ Treg cells\[[@B14]\], and they are associated with autoimmune disease progression\[[@B13],[@B15]-[@B17]\]. However, we are unaware of studies examining whether LAP^+^CD4^+^ T cells contribute to CRC progression. Thus, we analyzed the abundance, phenotype and cytokine secretion of LAP^+^CD4^+^ T cells in the tumor microenvironment in patients with CRC.

MATERIALS AND METHODS
=====================

Ethics statement
----------------

All patients enrolled in this study provided written informed consent. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki (Fortaleza, Brazil; October 2013), and it was approved by the Research Ethics Committee of the First Affiliated Hospital of Guangxi Medical University, China.

Study participants and samples
------------------------------

This study involved 50 patients who underwent primary tumor resection for colorectal adenocarcinoma at the First Affiliated Hospital of Guangxi Medical University from January to August 2014. Samples of peripheral blood were obtained preoperatively, and colorectal tumor and paratumor tissues were obtained postoperatively from each patient. Paratumor tissue samples were taken from tissue near the resection margin (≥ 10 cm away from the tumor site) that was confirmed to be tumor-free based on routine pathology. The basic data regarding the study population are shown in Table [1](#T1){ref-type="table"}.

###### 

Clinical characteristics of patients with colorectal cancer

  **Characteristics**         **Value[1](#T1FN1){ref-type="table-fn"}**
  --------------------------- -------------------------------------------
  Male                        31
  Female                      19
  Age, yr                     57.4 (37-76)
  Location of primary tumor   
  Colon                       22
  Rectum                      28
  TNM stage                   
  I/II                        23
  III/IV                      27

Values are *n* or mean (range).

Patients were excluded if they (1) had already undergone CRC surgery or had been diagnosed with locoregional recurrence; or (2) were receiving any anticancer therapy, corticosteroids or other nonsteroidal anti-inflammatory drugs at the time of peripheral venous blood collection.

During the study period, peripheral blood was also collected from 25 healthy donors serving as a control group. Healthy controls were free of chronic pain, cardiovascular complaints, or other chronic inflammatory diseases. They were matched with patients in age and sex and showed no significant differences from patients.

Cell isolation
--------------

Peripheral blood mononuclear cells (PBMCs) were isolated from patients using Ficoll density gradient centrifugation. Fresh tumor and paratumor samples were washed three times in RPMI 1640; after which, fatty, connective and necrotic tissues were removed. Samples were cut into 1-2-mm cubes, transferred to a 50-mL beaker, and incubated for 3 h at room temperature with a triple-enzyme digestion medium containing 1 mg/mL collagenase IV, 30 μg/mL DNase I and 0.1 mg/mL hyaluronidase (Sigma, St. Louis, MO, United States). Dissociated cell suspensions were filtered through a 70-μm nylon mesh, then tumor-infiltrating lymphocytes (TILs) were isolated from cell suspensions using discontinuous density gradient centrifugation\[[@B18]\]. LAP^-^CD4^+^ T cells and LAP^+^CD4^+^ T cells were isolated using a Magnetic cell sorting system (Miltenyi Biotec, Bergisch Gladbach, Germany). Cell purity was analyzed by flow cytometry as described below.

Flow cytometry
--------------

TILs and PBMCs were stimulated in culture for 4 h at 37 °C with 50 ng/mL phorbol-12-myristate-13-acetate, 1 μg/mL ionomycin, and 0.7 μl/mL GolgiStop reagent in a 5% CO~2~ incubator. T cells were identified based on surface or intracellular expression of markers labeled using antibodies (eBioscience, San Diego, CA, United States) against the following human antigens: LAP, CD4, forkhead box (Fox)p3, cytotoxic T-lymphocyte-associated protein (CTLA)-4, chemokine CC receptor (CCR)4, and CCR5. Antibodies were conjugated with one of the following fluorophores: phycoerythrin (PE), fluorescein isothiocyanate, PEcy5.5, PEcy7, peridinin chlorophyll protein (PerCP)-cy5.5, or allophycocyanin. Labeled cell suspensions were analyzed using a FACS Calibur flow cytometer (BD Bioscience, Franklin Lakes, NJ, United States) and FlowJo software (Tree Star, Ashland, OR, United States).

Real-time quantitative polymerase chain reaction
------------------------------------------------

Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, United States), and first-strand cDNA was generated using oligo (dT) primers and the SuperScript III First-Strand Synthesis System (Invitrogen). Levels of mRNAs encoding cytokines secreted by LAP^+^CD4^+^ T cells and LAP^-^CD4^+^ T cells (TGF-β, INF-γ, IL-2, IL-4, IL-10 and IL-17) were determined using SYBR-based real-time polymerase chain reaction (7500 StepOnePlus system, Applied Biosystems, Carlsbad, CA, United States) and primers purchased from TaKaRa Biosystems (Table [2](#T2){ref-type="table"}). Relative expression levels were calculated using the 2^-ΔΔCT^ method and normalized to levels of β-actin mRNA.

###### 

Primer sequences for polymerase chain reaction

  **Gene**                     **Sequence (5'-3')**          **Product (bp)**   **T (°C)**
  ---------------------------- ----------------------------- ------------------ ------------
  *IL-2*                       F:5' CAGCTACAACTGGAGCATTTAC   130                60
  R:5' TCAGTTCTGTGGCCTTCTTG                                                     
  *IL-4*                       F:5' GACCGTAACAGACATCTTTGC    180                60
  R:5' TCGAGCCGTTTCAGGAAT                                                       
  *IL-10*                      F:5' TTGCCAAGCCTTGTCTGA       160                60
  R:5' ACAGGGAAGAAATCGATGAC                                                     
  *IL-17*                      F:5' CCTCAGAGATCAACAGACCAA    80                 60
  R:5' GGTGCCTTGATCAGACAGAA                                                     
  *IFN-g*                      F:5' GGCAAGGCTATGTGATTACA     180                60
  R:5' TAAAGCACTGGCTCAGATTG                                                     
  *TGF-β1*                     F:5' CACGTGGAGCTGTACCAGAA     219                60
  R:5' GAACCCGTTGATGTCCACTT                                                     
  *18srRNA*                    F:5' CCTGGATACCGCAGCTAGGA     112                60
  R:5' GCGGCGCAATACGAATGCCCC                                                    

Statistical analysis
--------------------

Data were expressed as mean ± SD. Differences between two groups were assessed for significance using the Mann-Whitney *U* test, *t*-test, or paired *t*-test, as appropriate. All statistical tests were performed using SPSS version 16.0 (SPSS, Chicago, IL, United States), and the threshold of significance was defined as *P* \< 0.05.

RESULTS
=======

LAP^+^CD4^+^ T cells are elevated in PBMCs and tumor tissue of CRC patients
---------------------------------------------------------------------------

PBMCs were isolated preoperatively and TILs were isolated postoperatively from patients who underwent radical resection for CRC. To understand further the roles of LAP^+^CD4^+^ T cells in the tumor microenvironment in patients with CRC, the proportion of LAP^+^CD4^+^ T cells in PBMCs and tissues was detected by flow cytometry (Figure [1](#F1){ref-type="fig"}). The proportion of LAP^+^CD4^+^ T cells was significantly higher in peripheral blood from patients (9.44% ± 3.18%) than healthy controls (1.49% ± 1.00%, *P* \< 0.001; Figure [1B](#F1){ref-type="fig"} and C). Among CRC patients, the proportion of LAP^+^CD4^+^ T cells was significantly higher in tumor tissue (11.76% ± 3.74%) compared with paratumor tissue (3.87% ± 1.64%, *P* \< 0.001; Figure [1B](#F1){ref-type="fig"} and D).

![Abundance of LAP^+^CD4^+^ T cells in the colorectal cancer microenvironment based on flow cytometry. A: Gated on FSC/SSC, the proportion of LAP^+^CD4^+^ T cells in the CD4^+^ subset is presented in quadrant Q2; B: Flow cytometry to measure the proportion of LAP^+^CD4^+^ T cells in PBMCs and tissues; C: Proportion of LAP^+^CD4^+^ T cells in PBMCs; D: Proportion of LAP^+^CD4^+^ T cells in tissues.](WJG-23-455-g001){#F1}

Relationship between proportion of LAP^+^CD4^+^ T cells in tumor tissues and clinicopathological characteristics of CRC
-----------------------------------------------------------------------------------------------------------------------

We also observed positive correlations between the proportion of LAP^+^CD4^+^ T cells and TNM stage (*P* \< 0.001; Figure [2A](#F2){ref-type="fig"}), distant metastasis (*P* \< 0.001; Figure [2B](#F2){ref-type="fig"}) and serum level of carcinoembryonic antigen (CEA) (*P* \< 0.05; Figure [2C](#F2){ref-type="fig"}) (Table [3](#T3){ref-type="table"}).

![Correlation of LAP^+^CD4^+^ Treg cell abundance with clinicopathological characteristics of colorectal cancer, based on flow cytometry. A: TNM stage; B: Distant metastasis; C: Level of CEA.](WJG-23-455-g002){#F2}

###### 

Proportions of LAP^+^CD4^+^ T cells in tumor tissues and in relation to clinicopathological characteristics

                         ***n***   **LAP^+^CD4^+^ Treg (%)**   ***t***   ***P* value**   **95%CI**
  ---------------------- --------- --------------------------- --------- --------------- ------------
  Age, yr                                                                                
  \< 60                  29        11.15 ± 2.03                0.747     0.458           -1.35-2.94
  ≥ 60                   21        11.96 ± 4.51                                          
  Sex                                                                                    
  Male                   31        11.37 ± 3.24                0.444     0.659           -1.60-2.50
  Female                 19        11.82 ± 3.89                                          
  Location                                                                               
  Colon                  22        10.35 ± 3.45                0.652     0.517           -1.11-2.18
  Rectum                 28        11.89 ± 3.17                                          
  TNM stage                                                                              
  I/II                   23        8.45 ± 2.98                 4.973     0.000           3.85-9.07
  III/IV                 27        14.90 ± 5.58                                          
  Pathological pattern                                                                   
  Tubular/ papillary     43        11.09 ± 3.54                1.335     0.188           -0.73-3.60
  Myxoma/ ring cell      7         12.83 ± 3.26                                          
  Differentiation                                                                        
  High                   42        10.50 ± 3.22                0.877     0.385           -1.45-3.70
  Low                    8         12.43 ± 3.87                                          
  Metastasis                                                                             
  Yes                    9         12.51 ± 4.17                4.322     0.000           2.49-6.82
  No                     41        7.85 ± 2.61                                           
  Ileus                                                                                  
  Yes                    9         12.22 ± 3.49                0.904     0.470           -1.30-3.44
  No                     41        11.15 ± 3.14                                          
  CEA (ng/mL)                                                                            
  ≤ 5                    34        9.94 ± 3.15                 2.692     0.010           0.81-5.58
  \> 5                   16        13.13 ± 4.06                                          
  CA199 (U/mL)                                                                           
  ≤ 37                   32        11.34 ± 3.21                0.854     0.370           -1.51-3.85
  \> 37                  18        12.42 ± 4.35                                          

LAP^+^CD4^+^ Treg cell phenotype in CRC microenvironment
--------------------------------------------------------

Further studies of phenotypic marker expression revealed differences between LAP^+^CD4^+^ T cells and LAP^-^CD4^+^ T cells. In contrast to LAP^-^CD4^+^ T cells, LAP^+^CD4^+^ T cells showed lower Foxp3 expression but significantly higher levels of CTLA-4, CCR4 and CCR5 (*P* \< 0.01; Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}).

![Expression of phenotypic markers by LAP^+^CD4^+^ T cells and LAP^-^CD4^+^ T cells. A: Typical histograms of the expression of Foxp3, CTLA, CCR4 and CCR5 in LAP^+^CD4^+^ T cells or LAP^-^CD4^+^ T cells are depicted. The expression levels of Foxp3, CTLA, CCR4 and CCR5 were measured and compared between LAP^+^CD4^+^ T cells and LAP^-^CD4^+^ T cells; B: Foxp3; C: CTLA-4; D: CCR4; E: CCR5.](WJG-23-455-g003){#F3}

![Purity of cells. A: LAP+CD4+ T cells; B: LAP−CD4+ T.](WJG-23-455-g004){#F4}

Magnetic-activated cell sorting in vitro
----------------------------------------

Magnetic-activated cell sorting gave an overall enrichment of LAP^+^CD4^+^ T cells (95.02% ± 2.87%; Figure [3A](#F3){ref-type="fig"}) and enrichment was similar for LAP^-^CD4^+^ T cells (94.75% ± 2.76%; Figure [3B](#F3){ref-type="fig"}).

Cytokine expression
-------------------

The expression levels of cytokine profiles were measured by real-time qPCR, LAP^+^CD4^+^ T cells expressed significantly larger amounts of IL-10 and TGF-β but lower levels of IL-2, IL-4, IL-17 and IFN-γ, compared with LAP^-^CD4^+^ T cells (Table [4](#T4){ref-type="table"}).

###### 

Cytokine expression by LAP^+^CD4^+^ T cells and LAP^-^CD4^+^ T cells in colorectal cancer microenvironment

                 **IL-2**      **IL-4**      **IL-10**     **IL-17**     **IFN-g**     **TGF-β**
  -------------- ------------- ------------- ------------- ------------- ------------- -------------
  LAP^+^CD4^+^   0.22 ± 0.01   0.32 ± 0.12   1.13 ± 0.23   0.38 ± 0.10   0.18 ± 0.08   1.40 ± 0.15
  LAP^-^CD4^+^   1.49 ± 0.37   0.86 ± 0.23   0.86 ± 0.22   0.98 ± 0.23   0.69 ± 0.21   0.89 ± 0.11
  *t*            8.811         5.505         -2.327        6.435         5.981         -7.316
  *P* value      0.000         0.000         0.038         0.000         0.000         0.000

DISCUSSION
==========

Many carcinomas, including colorectal, gastric and nasopharyngeal cancer, are associated with elevated numbers of Treg cells\[[@B19]-[@B21]\], and it is suggested that Treg cells promote tumor development and metastasis by inhibiting the proliferation of effector T lymphocytes\[[@B22]\]. LAP^+^CD4^+^ T cells, a recently identified subset of CD4^+^ Treg cells, have 50-fold more potent immunosuppressive activity than traditional CD4^+^CD25^+^ T cells\[[@B13],[@B23]\]. Here we present several lines of evidence correlating LAP^+^CD4^+^ T cells with CRC progression. These cells were more abundant in peripheral blood and tumor tissue from patients with CRC compared with healthy controls. In CRC patients, the abundance of these cells correlated positively with TNM stage, metastasis, and serum level of CEA. CEA is the most widely used serum marker and is related to the prognosis of patients with CRC. The main use of CEA in CRC is in surveillance following curative resection for primary cancer\[[@B24],[@B25]\]. These results suggest that LAP^+^CD4^+^ T cells, like traditional CD4^+^CD25^+^ Treg cells, accumulate in the tumor microenvironment and postoperative monitoring of the LAP^+^CD4^+^ T cells in CRC patients may be useful for assessing prognosis and predicting distant metastasis.

In our study, expression of CCR4 and CCR5 was higher in LAP^+^CD4^+^ T cells than in LAP^-^CD4^+^ T cells. CCR4 and CCR5 are highly expressed in tumor microenvironments and appear to act as proinflammatory cytokine receptors\[[@B26],[@B27]\]. Some studies have reported that CCR4 and its ligands are associated with increased tumor recurrence and impaired overall survival in patients with gastric cancer\[[@B28],[@B29]\]. Wang et al\[[@B30]\] have shown that the CCL5/CCR5 axis modulates angiogenesis and metastasis that dictate cancer development in the tumor microenvironment. We identified similarities and differences between LAP^+^CD4^+^ T cells and traditional CD4^+^CD25^+^ Treg cells. Foxp3, previously identified as important in the differentiation and development of Treg cells\[[@B31],[@B32]\], was expressed at detectable levels in only 4% of LAP^+^CD4^+^ T cells. This means that LAP^+^CD4^+^ T cells differ from traditional CD4^+^CD25^+^ Treg cells in marker expression and their immunosuppressive activity is independent of Foxp3. In contrast, LAP^+^CD4^+^ T cells expressed abundant levels of CTLA-4, which is used by CD4^+^CD25^+^ Treg cells to modulate immune responses\[[@B33]\]. CTLA-4 on CD4^+^CD25^+^ Treg cells has been shown to suppress immune function through several mechanisms\[[@B34],[@B35]\]: increasing numbers of CD4^+^CD25^+^ CTLA-4 T cells; inhibiting production of proinflammatory factors such as IFN-γ; increasing production of IL-2, IL-4, IL-10 and TGF-β1; and blocking tryptophan synthesis by antigen-presenting cells\[[@B36]\]. Under normal circumstances, these mechanisms can promote self-tolerance and prevent autoimmune disease and transplant rejection. Our results suggest that the CTLA-4 on LAP^+^CD4^+^ T cells help CRC tumors evade the host immune system, and one mechanism may be by inhibiting proliferation of effector T lymphocytes.

Our results reproduce most of those of Mahalingam et al\[[@B37]\], using different procedures. We isolated LAP^+^CD4^+^ T cells and LAP^-^CD4^+^ T cells using a magnetic cell sorting system and analyzed cell purity by flow cytometry. Our results revealed that, after sorting, the purity of these two cells was \> 90%. This is the first time that LAP^+^CD4^+^ T cells were isolated using a magnetic cell sorting system. In contrast to Mahalingam et al\[[@B37]\], we found that LAP^+^CD4^+^ T cells expressed high levels of IL-10 and TGF-β. These cytokines play key roles in suppressing immune responses in mouse models of cerebral meningitis and allergic inflammation\[[@B13],[@B38],[@B39]\]. The immunoregulatory activity of Treg cells has been linked to several molecules, such as CTLA-4, TGF-β, and IL-10\[[@B40],[@B41]\]. TGF-β has been shown to play an important role in the differentiation, maintenance and function of natural Treg cells\[[@B42]-[@B45]\]. However, several studies have revealed the role of IL-10 in Treg cell suppression. It has been demonstrated that IL-10 is required for the homeostatic maintenance of the T cell number by Treg cells\[[@B46]\] and is involved in Treg-cell-mediated suppression in murine models of transplantation, graft-versus-host disease, chronic parasite infection, colitis, and a rat model of type 1 diabetes\[[@B47]\]. Like classical CD4^+^CD25^+^ Treg cells, our experiments suggest that the immunosuppressive activity of LAP^+^CD4^+^ T cells could be mediated by IL-10 and TGF-β.

In conclusion, we provide evidence that patients with CRC have elevated proportions of LAP^+^CD4^+^ T cells in the peripheral blood and tumor microenvironment, and their accumulation at tumor sites correlates with CEA level, TNM stage and distant metastasis. LAP^+^CD4^+^ T cells express high levels of IL-10 and TGF-β, which may be involved in tumor immune evasion. Our findings suggest that investigating the functions and regulation of LAP^+^CD4^+^ T cells in CRC may improve our understanding of disease progression and treatment.
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